BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36183438)

  • 21. [Reappraisals of biological behaviors of PDGFRA mutant gastrointestinal stromal tumor].
    Yuan W; Huang W; Ren L; Liang HY; Dong SY; Du XY; Xu C; Fang Y; Shen KT; Hou YY
    Zhonghua Bing Li Xue Za Zhi; 2024 Jan; 53(1):46-51. PubMed ID: 38178746
    [No Abstract]   [Full Text] [Related]  

  • 22. [Status and clinical implication of c-kit and PDGFRA mutations in 165 cases of gastrointestinal stromal tumor (GIST)].
    He HY; Fang WG; Zhong HH; Li Y; Zheng J; Du J; Heng WJ; Wu BQ
    Zhonghua Bing Li Xue Za Zhi; 2006 May; 35(5):262-6. PubMed ID: 16776995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [c-kit and PDGFRA mutations in 60 cases of gastrointestinal stromal tumors (GISTs)].
    He HY; Xiang YN; Li Y; Zhong HH; Wu BQ; Zheng J
    Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Jun; 37(3):320-4. PubMed ID: 15968329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Morphological Correlates of KIT and PDGFRA Genotypes in Gastrointestinal Stromal Tumour.
    Priya V; Kumari N; Krishnani N
    Turk Patoloji Derg; 2020; 36(2):116-125. PubMed ID: 31538651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.
    Cassier PA; Fumagalli E; Rutkowski P; Schöffski P; Van Glabbeke M; Debiec-Rychter M; Emile JF; Duffaud F; Martin-Broto J; Landi B; Adenis A; Bertucci F; Bompas E; Bouché O; Leyvraz S; Judson I; Verweij J; Casali P; Blay JY; Hohenberger P;
    Clin Cancer Res; 2012 Aug; 18(16):4458-64. PubMed ID: 22718859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [c-Kit and PDGFRA mutations and clinico-morphological features of gastrointestinal stromal tumors].
    Beliakov IS; Anurova OA; Snigur PV; Tsyganova IV; Sel'chuk VIu; Mazurenko NN
    Vopr Onkol; 2007; 53(6):677-81. PubMed ID: 18416137
    [TBL] [Abstract][Full Text] [Related]  

  • 27. KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: a population-based study.
    Rossi S; Gasparotto D; Miceli R; Toffolatti L; Gallina G; Scaramel E; Marzotto A; Boscato E; Messerini L; Bearzi I; Mazzoleni G; Capella C; Arrigoni G; Sonzogni A; Sidoni A; Mariani L; Amore P; Gronchi A; Casali PG; Maestro R; Dei Tos AP
    Am J Surg Pathol; 2015 Jul; 39(7):922-30. PubMed ID: 25970686
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity.
    Weisberg E; Wright RD; Jiang J; Ray A; Moreno D; Manley PW; Fabbro D; Hall-Meyers E; Catley L; Podar K; Kung AL; Griffin JD
    Gastroenterology; 2006 Dec; 131(6):1734-42. PubMed ID: 17087936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.
    Kang YK; George S; Jones RL; Rutkowski P; Shen L; Mir O; Patel S; Zhou Y; von Mehren M; Hohenberger P; Villalobos V; Brahmi M; Tap WD; Trent J; Pantaleo MA; Schöffski P; He K; Hew P; Newberry K; Roche M; Heinrich MC; Bauer S
    J Clin Oncol; 2021 Oct; 39(28):3128-3139. PubMed ID: 34343033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gene Expression Profiling of PDGFRA Mutant GIST Reveals Immune Signatures as a Specific Fingerprint of D842V Exon 18 Mutation.
    Indio V; Ravegnini G; Astolfi A; Urbini M; Saponara M; De Leo A; Gruppioni E; Tarantino G; Angelini S; Pession A; Pantaleo MA; Nannini M
    Front Immunol; 2020; 11():851. PubMed ID: 32670260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy.
    George S; Jones RL; Bauer S; Kang YK; Schöffski P; Eskens F; Mir O; Cassier PA; Serrano C; Tap WD; Trent J; Rutkowski P; Patel S; Chawla SP; Meiri E; Gordon M; Zhou T; Roche M; Heinrich MC; von Mehren M
    Oncologist; 2021 Apr; 26(4):e639-e649. PubMed ID: 33453089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The analysis of status and clinical implication of KIT and PDGFRA mutations in gastrointestinal stromal tumor (GIST).
    Du CY; Shi YQ; Zhou Y; Fu H; Zhao G
    J Surg Oncol; 2008 Sep; 98(3):175-8. PubMed ID: 18618605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. KIT and PDGFRa mutational patterns in Sardinian patients with gastrointestinal stromal tumors.
    Palomba G; Paliogiannis P; Sini MC; Colombino M; Casula M; Manca A; Pisano M; Sotgiu G; Doneddu V; Palmieri G; Cossu A
    Eur J Cancer Prev; 2021 Jan; 30(1):53-58. PubMed ID: 32091431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PDGFRA and KIT Mutation Status and Its Association With Clinicopathological Properties, Including DOG1.
    Baskin Y; Kocal GC; Kucukzeybek BB; Akbarpour M; Kayacik N; Sagol O; Ellidokuz H; Oztop I
    Oncol Res; 2016; 24(1):41-53. PubMed ID: 27178821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis.
    Andersson J; Bümming P; Meis-Kindblom JM; Sihto H; Nupponen N; Joensuu H; Odén A; Gustavsson B; Kindblom LG; Nilsson B
    Gastroenterology; 2006 May; 130(6):1573-81. PubMed ID: 16697720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors.
    Rossi S; Sbaraglia M; Dell'Orto MC; Gasparotto D; Cacciatore M; Boscato E; Carraro V; Toffolatti L; Gallina G; Niero M; Pilozzi E; Mandolesi A; Sessa F; Sonzogni A; Mancini C; Mazzoleni G; Romeo S; Maestro R; Dei Tos AP
    Oncotarget; 2016 May; 7(21):30109-18. PubMed ID: 27097112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene.
    Indio V; Astolfi A; Tarantino G; Urbini M; Patterson J; Nannini M; Saponara M; Gatto L; Santini D; do Valle IF; Castellani G; Remondini D; Fiorentino M; von Mehren M; Brandi G; Biasco G; Heinrich MC; Pantaleo MA
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29510530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. KIT-negative gastrointestinal stromal tumor of the abdominal soft tissue: a clinicopathologic and genetic study of 10 cases.
    Yamamoto H; Kojima A; Nagata S; Tomita Y; Takahashi S; Oda Y
    Am J Surg Pathol; 2011 Sep; 35(9):1287-95. PubMed ID: 21836495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anaplastic lymphoma kinase expression in PDGFRA-mutated gastrointestinal stromal tumors probably correlates with poor prognosis.
    Wu Y; Gao B; Xia Q; Zhu Y; Wang N; Chang X; Huang B; Luo D; Zhang J; Zhang P; Shi H; Fan J; Nie X
    World J Surg Oncol; 2023 Apr; 21(1):138. PubMed ID: 37120571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myosin Light-Chain Kinase Inhibition Potentiates the Antitumor Effects of Avapritinib in PDGFRA D842V-Mutant Gastrointestinal Stromal Tumor.
    Rossi F; Liu M; Tieniber A; Etherington MS; Hanna A; Vitiello GA; Param NJ; Do K; Wang L; Antonescu CR; Zeng S; Zhang JQ; DeMatteo RP
    Clin Cancer Res; 2023 Jun; 29(11):2144-2157. PubMed ID: 36971786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.